JP2024520666A5 - - Google Patents
Info
- Publication number
- JP2024520666A5 JP2024520666A5 JP2023574453A JP2023574453A JP2024520666A5 JP 2024520666 A5 JP2024520666 A5 JP 2024520666A5 JP 2023574453 A JP2023574453 A JP 2023574453A JP 2023574453 A JP2023574453 A JP 2023574453A JP 2024520666 A5 JP2024520666 A5 JP 2024520666A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tce
- amino acid
- acid sequence
- molecule according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197265P | 2021-06-04 | 2021-06-04 | |
| US63/197,265 | 2021-06-04 | ||
| US202163236547P | 2021-08-24 | 2021-08-24 | |
| US63/236,547 | 2021-08-24 | ||
| PCT/US2022/032006 WO2022256559A1 (en) | 2021-06-04 | 2022-06-02 | T cell engager molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520666A JP2024520666A (ja) | 2024-05-24 |
| JP2024520666A5 true JP2024520666A5 (enExample) | 2025-06-09 |
Family
ID=82258382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574453A Pending JP2024520666A (ja) | 2021-06-04 | 2022-06-02 | Ｔ細胞エンゲージャ分子及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250129160A1 (enExample) |
| EP (1) | EP4347654A1 (enExample) |
| JP (1) | JP2024520666A (enExample) |
| KR (1) | KR20240019218A (enExample) |
| AU (1) | AU2022287014A1 (enExample) |
| CA (1) | CA3221250A1 (enExample) |
| IL (1) | IL308809A (enExample) |
| MX (1) | MX2023014415A (enExample) |
| WO (1) | WO2022256559A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022285741A1 (en) * | 2021-06-04 | 2023-12-14 | Amgen Inc. | Anti-ccr8 antibodies and uses thereof |
| PE20240638A1 (es) | 2021-07-14 | 2024-03-27 | Genentech Inc | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso |
| PE20252286A1 (es) * | 2023-01-18 | 2025-09-18 | Genentech Inc | Anticuerpos multiespecificos y usos de estos |
| WO2024248037A1 (ja) * | 2023-05-30 | 2024-12-05 | 塩野義製薬株式会社 | Ｃｃｒ８を抗原として認識する二重特異性抗体 |
| CN122374018A (zh) * | 2023-10-06 | 2026-07-10 | 美国安进公司 | 用于癌症治疗的组合疗法 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025259749A1 (en) * | 2024-06-12 | 2025-12-18 | Amgen Inc. | Stable single-chain variable fragments |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2026019990A1 (en) * | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
| WO2026072755A2 (en) * | 2024-09-26 | 2026-04-02 | Amgen Inc. | Single-chain fab proteins and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| EP3218413A4 (en) * | 2014-11-12 | 2018-03-28 | Memorial Sloan-Kettering Cancer Center | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| UA126657C2 (uk) * | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| AR107582A1 (es) * | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| JP7231158B2 (ja) * | 2016-10-19 | 2023-03-01 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | Ｃｄ１３３結合剤およびその使用 |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| CN110835371A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| BR112021011431A2 (pt) * | 2018-12-27 | 2021-11-23 | Univ Osaka | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit |
-
2022
- 2022-06-02 IL IL308809A patent/IL308809A/en unknown
- 2022-06-02 MX MX2023014415A patent/MX2023014415A/es unknown
- 2022-06-02 CA CA3221250A patent/CA3221250A1/en active Pending
- 2022-06-02 EP EP22734448.8A patent/EP4347654A1/en active Pending
- 2022-06-02 US US18/566,228 patent/US20250129160A1/en active Pending
- 2022-06-02 WO PCT/US2022/032006 patent/WO2022256559A1/en not_active Ceased
- 2022-06-02 JP JP2023574453A patent/JP2024520666A/ja active Pending
- 2022-06-02 KR KR1020247000080A patent/KR20240019218A/ko active Pending
- 2022-06-02 AU AU2022287014A patent/AU2022287014A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025111463A5 (enExample) | ||
| CN111148761B (zh) | 多特异性抗体及其制备和使用方法 | |
| JP7474193B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2023123726A5 (enExample) | ||
| JP2020019787A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2020528768A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| JP2019513701A5 (enExample) | ||
| JP2025038088A5 (enExample) | ||
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2024531409A5 (enExample) | ||
| JP2011501656A5 (enExample) | ||
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JP2025183307A5 (enExample) | ||
| JP2021531732A5 (enExample) | ||
| JP2021512613A5 (enExample) | ||
| JP2023518153A5 (enExample) | ||
| RU2014109093A (ru) | Антитела против нейрегулина и их применение | |
| JP2024533067A5 (enExample) | ||
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| JP2025511135A5 (enExample) | ||
| JP2018529328A5 (enExample) | ||
| CN120603850A (zh) | 抗cmet抗体及使用方法 |